Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATFORM Study of Precision Medicine for Rare Tumors
NCT04423185Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2020
- Primary completion
- Jul 2026
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label trial of almonertinib, dacomitinib, alectinib, crizotinib, vemurafenib and 6 more in solid tumor, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate at 2 years. Started Aug 2020; status: recruiting.
02
Drugs
almonertinibdacomitinibalectinibcrizotinibvemurafenib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04423185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04423185.